Sanofi Sees Trend for Years of Steady Growth: CFO

The video discusses Sanofi's financial performance in 2022, highlighting a 7% growth in top-line revenue and a 17% increase in EPS. The company is optimistic about future growth despite some challenges, such as the Aubagio LOL. Sanofi's M&A strategy focuses on internal investment and deals in immunology and oncology. Dupixent, a key product, is expected to grow significantly, with potential new indications. New product launches like Bay Fortus and Altivo are seen as game changers. The Zantac litigation is addressed, with Sanofi confident in its legal position and future growth plans.

What is the significance of the upcoming launches mentioned in the interview?

What was the impact of the litigation surrounding Zantac on Sanofi's share price?

What is the company's strategy regarding the development of innovative drugs?